Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 3/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834342 | 1.00 | CD38 (0.47) | CD38KAT2BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29182217 | 1.00 | CD38 (0.47) | CD38KAT2BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30363649 | 0.88 | CD38 (0.62) | CD38 | |
| SCHEMBL25136139 | 0.88 | CD38 (0.62) | CD38 | |
| SCHEMBL29182230 | 0.88 | CD38 (0.62) | CD38 | |
| SCHEMBL25136114 | 0.87 | CD38 (0.44) | CD38NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29182198 | 0.87 | CD38 (0.44) | CD38NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30363781 | 0.87 | CD38 (0.44) | CD38NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25136201 | 0.85 | CD38 (0.46) | CD38CNR1 | |
| SCHEMBL25136180 | 0.80 | CD38 (0.43) | CD38TAS1R3TAS1R1TAS1R2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885KAT2B 2837/4885TAS1R3 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.